AI Collaboration Between Sanofi and Healx Will Target Novel Rare Diseases Indications
Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare disease targets.
Related Articles
SCS Researcher Develops Metagenomic Profiling Method
A new k-mer sketching metagenomic profiler allows scientists to analyze genomic data more quickly and precisely than other profilers.
A breakthrough cancer immunotherapy is now taking aim at autoimmune disease
CAR-T therapy is generating excitement for lupus, scleroderma, and other conditions as clinical trials expand
Robot watches how-to videos and becomes an expert surgeon
How-to videos are great for humans looking to pick up some quick skills. Now, it turns out they’re also great for robots looking to become…
Ireland’s SSPC and NIBRT Team to Take on Biopharma Bottlenecks
SSPC and NIBRT will use hybrid modeling techniques to improve process development for advanced therapies under new collaboration.
Enhancing Value in Advanced Therapy Manufacturing
Most discussion of gene and cell therapy costs focuses on increasing manufacturing efficiency but reducing costs can only go so far.
Amazon gets FAA approval for new delivery drone as it begins tests in Arizona
Amazon says it has received approval from the FAA to fly its newer, smaller delivery drones, including beyond the visual line of sight of pilots.
Single-Cell Lipid Characterization for Bioprocess Operations
Researchers developed a high-throughput microfluidics-based method to measure and analyze lipids in single living cells using LC-MS.
Pathogenic proteotoxicity of cryptic splicing is alleviated by ubiquitination and ER-phagy
RNA splicing enables the functional adaptation of cells to changing contexts. Impaired splicing has been associated with diseases, including retinitis pigmentosa, but the underlying molecular…
Driving Innovation from Biology Insight to Novel Therapeutic with Computational Solutions
© 2024 Mary Ann Liebert, Inc. Publishers. All rights reserved.